Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database

Abstract Background The combination regimen with immune checkpoint inhibitors (ICIs) and other therapies has been widely applied for patients with non-small-cell lung cancer (NSCLC). To date, no literature has systematically addressed the risk of hepatitis associated with the combination therapy. We...

Descrición completa

Detalles Bibliográficos

Principais autores:	Zhaohui Li, Zixiang Zhou, Nan Zhang, Binhe Tian, Xiangqi Chen, Haitao Zhao, Hanping Wang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Springer 2024-11-01
Series:	Cancer Immunology, Immunotherapy
Assuntos:	Immune checkpoint inhibitors Targeted therapy Pharmacovigilance Adverse events Hepatitis
Acceso en liña:	https://doi.org/10.1007/s00262-024-03858-4
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!